DEFB1 and colorectal carcinoma: Highlighting the need for early detection and novel CRC therapies, it examines HBD-1’s ability to inhibit the mTOR pathway, a key regulator of cell growth, positioning defensin-based treatments as a promising approach with evidence for suppressing cancer cell proliferation and tumor growth.